Recursion Pharmaceuticals, Inc. RXRX Q2 2025 earnings
Reported August 5, 2025 · Before market open
Revenue$19.1MMiss by $822.0K
EPS-$0.41Miss by $0.06
Revenue estimate$19.9M
EPS estimate-$0.35
Next report
Aug 4, 2026 (In 6 days)Revenue estimate$11.0M
EPS estimate-$0.25
Financials
Q2 2025Valuation & ratios
Segments
Versus estimates
Revenue
Diluted EPS
Ask the moment Recursion Pharmaceuticals, Inc. reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did Recursion Pharmaceuticals, Inc. report Q2 2025 earnings?
- Recursion Pharmaceuticals, Inc. (RXRX) reported Q2 2025 earnings on August 5, 2025 before market open.
- What were Recursion Pharmaceuticals, Inc.'s Q2 2025 revenue and EPS?
- Recursion Pharmaceuticals, Inc. reported revenue of $19.1M and eps of $-0.41 for Q2 2025.
- Did Recursion Pharmaceuticals, Inc. beat estimates in Q2 2025?
- Revenue missed the consensus estimate of $19.9M by $822.0K. EPS missed the consensus estimate of $-0.35 by $0.06.
- How did Recursion Pharmaceuticals, Inc.'s Q2 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 32.5% from $14.4M a year earlier and eps declined 2.5% from $-0.40.
- Where can I find Recursion Pharmaceuticals, Inc.'s Q2 2025 SEC filings?
- You can read the 10-Q periodic report (0001601830-25-000127) directly on SEC EDGAR. The filing index links above go to sec.gov.